|
Contents
|
|
|
|
Brain Tumors |
|
|
|
|
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E,
Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P,
Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R,
Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A,
Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B,
Simon R, Steinhausen HC, Stovner LJ, Vallat JM, den Bergh PV, van Os J, Vos
P, Xu W, Wittchen HU, Jönsson B, Olesen J; on behalf of the CDBE2010 study
group.
Cost of disorders of the brain in Europe 2010.
Eur Neuropsychopharmacol. 2011 Sep 14;. [Epub ahead of print]
.JPG) Abstract | .gif)
Related articles
|
|
L. Kutikova, L. Bowman, S. Chang, S. Long
How costly is brain cancer? Healthcare services use and costs from across the US
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1559
|
|
|
Glioblastoma |
|
|
|
|
Lamers LM, Stupp R, van den Bent MJ, Al MJ,
Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA
Cost-effectiveness of temozolomide for the treatment of newly diagnosed
glioblastoma multiforme : a report from the EORTC 26981/22981 NCI-C CE3
Intergroup Study
Cancer. 2008 Jan 22; [Epub
ahead of print]
Abstract
|
|
|
Uyl-de
Groot CA, Stupp R, van der Bent M.
Cost-effectiveness of temozolomide for the treatment of newly diagnosed
glioblastoma multiforme
Expert Rev Pharmacoecon Outcomes Res. 2009 Jun;9(3):235-41
Abstract
|
|
|
|
|
